Evolution of Experimental Models of the Liver to Predict Human Drug Hepatotoxicity and Efficacy

Clinics in Liver Disease

Volumn 21, Issue 1, 2017, Pages 197-214

  Vernetti, Lawrence A ^a   Vogt, Andreas ^a   Gough, Albert ^a   Taylor, D Lansing ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Drug discovery; Drug induced liver injury; Human liver models; In vitro hepatotoxicity; Liver toxicology; Microphysiology liver; Quantitative system pharmacology

Indexed keywords

ANIMAL; ANIMAL MODEL; ASTRONOMY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; LIVER; MAMMAL; PRECLINICAL STUDY; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT; TOXIC HEPATITIS;

ANIMALS; CHEMICAL AND DRUG INDUCED LIVER INJURY; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; EVOLUTION, CHEMICAL; HUMANS; LIVER; MAMMALS; MODELS, ANIMAL; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT;

EID: 84995902491     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2016.08.013     Document Type: Review

References (71)

1. 1 Stern, A.M., Schurdak, M.E., Bahar, I., et al. A perspective on implementing a quantitative systems pharmacology platform for drug discovery and the advancement of personalized medicine. J Biomol Screen 21:6 (2016), 521–534.
2. 2 Sorger, P.K., Allerheiligen, S.B.R., Abernathy, D.R., et al. Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. In an NIH white paper by the QSP workshop group – October, 2011. 2011, NIH, Bethesda (MD) Ward R, Editor.
3. 3 Kaitin, K.I., DiMasi, J.A., Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther 89:2 (2011), 183–188.
4. 4 Laverty, H., Benson, C., Cartwright, E., et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. Br J Pharmacol 163:4 (2011), 675–693.
5. 5 Sacks, L.V., Shamsuddin, H.H., Yasinskaya, Y.I., et al. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. JAMA 311:4 (2014), 378–384.
6. 6 Stevens, J.L., Baker, T.K., The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 14:3–4 (2009), 162–167.
7. 7 Onakpoya, I.J., Heneghan, C.J., Aronson, J.K., Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med, 14, 2016, 10.
8. 8 Yuan, L., Kaplowitz, N., Mechanisms of drug-induced liver injury. Clin Liver Dis 17:4 (2013), 507–518 vii.
9. 9 Doull, J., Bruce, M., General principles of toicology. Klaassen, C.D., (eds.) Cassertt and Doull's toxicology: the basic science of poisons, 1986, Macmillan Publishing Company, New York, 11–32.
10. 10 Olson, H., Betton, G., Robinson, D., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:1 (2000), 56–67.
11. 11 Godoy, P., Hewitt, N.J., Albrecht, U., et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87:8 (2013), 1315–1530.
12. 12 Kubinyi, H., Drug research: myths, hype and reality. Nat Rev Drug Discov 2:8 (2003), 665–668.
13. 13 Ito, K., Houston, J.B., Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res 21:5 (2004), 785–792.
14. 14 Brandon, E.F., Raap, C.D., Meijerman, I., et al. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 189:3 (2003), 233–246.
15. 15 Soldatow, V.Y., Lecluyse, E.L., Griffith, L.G., et al. In vitro models for liver toxicity testing. Toxicol Res (Camb) 2:1 (2013), 23–39.
16. 16 Mennecozzi, M., et al. Hepatotoxicity screening taking a mode-of-action approach using HepaRG cells and HCA. Altex Proceedings 1 (2012), 193–204.
17. 17 Vernetti, L., et al. Cellular systems biology applied to preclinical safety testing: a case study of CellCiphr™ profiling. Ekins, S., Xu, J.J., (eds.) Drug efficacy, safety, and biologics discovery: Emerging technologies and tools, 2009, John Wiley & Sons, Hoboken (NJ), 53–73.
18. 18 Faris, R.A., Hong, Y.L., Liu, J., et al. Corning (R) hepatocell-cells closely model the behavior of parental cells for predicting hepatotoxicity. In drug metabolism reviews. 2015, Taylor & Francis Ltd, Abingdon (United Kingdom).
19. 19 Bi, Y.A., Kazolias, D., Duignan, D.B., Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos 34:9 (2006), 1658–1665.
20. 20 Wang, Y.M., Chai, S.C., Brewer, C.T., et al. Pregnane X receptor and drug-induced liver injury. Expert Opin Drug Metab Toxicol 10:11 (2014), 1521–1532.
21. 21 Usui, T., Mise, M., Hashizume, T., et al. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab Dispos 37:12 (2009), 2383–2392.
22. 22 Will, Y., Dykens, J., Mitochondrial toxicity assessment in industry–a decade of technology development and insight. Expert Opin Drug Metab Toxicol 10:8 (2014), 1061–1067.
23. 23 Aleo, M.D., Luo, Y., Swiss, R., et al. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 60:3 (2014), 1015–1022.
24. 24 Pereira, C.V., Nadanaciva, S., Oliveira, P.J., et al. The contribution of oxidative stress to drug-induced organ toxicity and its detection in vitro and in vivo. Expert Opin Drug Metab Toxicol 8:2 (2012), 219–237.
25. 25 Collins, F.S., Gray, G.M., Bucher, J.R., Toxicology. Transforming environmental health protection. Science 319:5865 (2008), 906–907.
26. 26 Blomme, E.A., Will, Y., Toxicology strategies for drug discovery: present and future. Chem Res Toxicol 29:4 (2016), 473–504.
27. 27 Chen, M., Bisgin, H., Tong, L., et al. Toward predictive models for drug-induced liver injury in humans: are we there yet?. Biomark Med 8:2 (2014), 201–213.
28. 28 Russell, W.M.S., Burch, R.L., The principles of humane experimental technique. 1959, Methuen, London, 238.
29. 29 Rubinstein, A.L., Zebrafish assays for drug toxicity screening. Expert Opin Drug Metab Toxicol 2:2 (2006), 231–240.
30. 30 McGrath, P., Li, C.Q., Zebrafish: a predictive model for assessing drug-induced toxicity. Drug Discov Today 13:9–10 (2008), 394–401.
31. 31 Hill, A., Mesens, N., Steemans, M., et al. Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development. Drug Metab Rev 44:1 (2012), 127–140.
32. 32 Zon, L.I., Peterson, R.T., In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 4:1 (2005), 35–44.
33. 33 Parng, C., In vivo zebrafish assays for toxicity testing. Curr Opin Drug Discov Devel 8:1 (2005), 100–106.
34. 34 Chu, J., Sadler, K.C., New school in liver development: lessons from zebrafish. Hepatology 50:5 (2009), 1656–1663.
35. 35 Behra, M., Etard, C., Cousin, X., et al. The use of zebrafish mutants to identify secondary target effects of acetylcholine esterase inhibitors. Toxicol Sci 77:2 (2004), 325–333.
36. 36 Jones, H.S., Panter, G.H., Hutchinson, T.H., et al. Oxidative and conjugative xenobiotic metabolism in zebrafish larvae in vivo. Zebrafish 7:1 (2010), 23–30.
37. 37 Poon, K.L., Wang, X., Ng, A.S., et al. Humanizing the zebrafish liver shifts drug metabolic profiles and improves pharmacokinetics of CYP3A4 substrates. Arch Toxicol, 2016 [Epub ahead of print].
38. 38 Wolf, J.C., Wolfe, M.J., A brief overview of nonneoplastic hepatic toxicity in fish. Toxicol Pathol 33:1 (2005), 75–85.
39. 39 He, J.H., Guo, S.Y., Zhu, F., et al. A zebrafish phenotypic assay for assessing drug-induced hepatotoxicity. J Pharmacol Toxicol Methods 67:1 (2013), 25–32.
40. 40 Murtha, J.M., Qi, W., Keller, E.T., Hematologic and serum biochemical values for zebrafish (Danio rerio). Comp Med 53:1 (2003), 37–41.
41. 41 Mesens, N., Crawford, A.D., Menke, A., et al. Are zebrafish larvae suitable for assessing the hepatotoxicity potential of drug candidates?. J Appl Toxicol 35:9 (2015), 1017–1029.
42. 42 Verstraelen, S., Peers, B., Maho, W., et al. Phenotypic and biomarker evaluation of zebrafish larvae as an alternative model to predict mammalian hepatotoxicity. J Appl Toxicol 36 (2016), 1194–1206.
43. 43 Abraham, V.C., Towne, D.L., Waring, J.F., et al. Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. J Biomol Screen 13:6 (2008), 527–537.
44. 44 Bhatia, S.N., Ingber, D.E., Microfluidic organs-on-chips. Nature, 201, 2014, 4.
45. 45 Wikswo, J., Annual thematic issue: the biology and medicine of microphysiological systems. [special issue] Exp Biol Med 239:9 (2014), 1061–1063.
46. 46 Nam, K.H., Smith, A.S., Lone, S., et al. Biomimetic 3D tissue models for advanced high-throughput drug screening. J Lab Autom 20:3 (2015), 201–215.
47. 47 Ouattara, D.A., Choi, S.H., Sakai, Y., et al. Kinetic modelling of in vitro cell-based assays to characterize non-specific bindings and ADME processes in a static and a perfused fluidic system. Toxicol Lett 205:3 (2011), 310–319.
48. 48 Vernetti, L.A., Senutovitch, N., Boltz, R., et al. A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp Biol Med (Maywood) 241:1 (2016), 101–114.
49. 49 Sarkar, U., Rivera-Burgos, D., Large, E.M., et al. Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor. Drug Metab Dispos 43:7 (2015), 1091–1099.
50. 50 Gough, A., Vernetti, L., Bergenthal, L., et al. The microphysiology systems database for analyzing and modeling compound interactions with human and animal organ models. Applied In Vitro Toxicology 2:2 (2016), 103–117.
51. 51 Senutovitch, N., Vernetti, L., Boltz, R., et al. Fluorescent protein biosensors applied to microphysiological systems. Exp Biol Med (Maywood) 240:6 (2015), 795–808.
52. 52 Cross H, Tower B. Pre-market evaluation of hepatotoxicity in health products, Health Canada Guidance document # 12-104742–88, 2012.
53. 53 Jia, L., Liu, X., The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr Drug Metab 8:8 (2007), 822–829.
54. 54 Kanebratt, K.P., Andersson, T.B., Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 36:7 (2008), 1444–1452.
55. 55 Ramaiahgari, S.C., den Braver, M.W., Herpers, B., et al. A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies. Arch Toxicol 88:5 (2014), 1083–1095.
56. 56 Wang, Z., Luo, X., Anene-Nzelu, C., et al. HepaRG culture in tethered spheroids as an in vitro three-dimensional model for drug safety screening. J Appl Toxicol 35:8 (2015), 909–917.
57. 57 Lubberstedt, M., Müller-Vieira, U., Mayer, M., et al. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J Pharmacol Toxicol Methods 63:1 (2011), 59–68.
58. 58 Greene, N., Fisk, L., Naven, R.T., et al. Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol 23:7 (2010), 1215–1222.
59. 59 Matthews, E.J., Ursem, C.J., Kruhlak, N.L., et al. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities. Regul Toxicol Pharmacol 54:1 (2009), 23–42.
60. 60 Cheng, A., Dixon, S.L., In silico models for the prediction of dose-dependent human hepatotoxicity. J Comput Aided Mol Des 17:12 (2003), 811–823.
61. 61 Liew, C.Y., Lim, Y.C., Yap, C.W., Mixed learning algorithms and features ensemble in hepatotoxicity prediction. J Comput Aided Mol Des 25:9 (2011), 855–871.
62. 62 Ekins, S., Williams, A.J., Xu, J.J., A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug Metab Dispos 38:12 (2010), 2302–2308.
63. 63 Persson, M., Løye, A.F., Mow, T., et al. A high content screening assay to predict human drug-induced liver injury during drug discovery. J Pharmacol Toxicol Methods 68:3 (2013), 302–313.
64. 64 Xu, J.J., Henstock, P.V., Dunn, M.C., et al. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105:1 (2008), 97–105.
65. 65 Khetani, S.R., Kanchagar, C., Ukairo, O., et al. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol Sci 132:1 (2013), 107–117.
66. 66 Sakatis, M.Z., Reese, M.J., Harrell, A.W., et al. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chem Res Toxicol 25:10 (2012), 2067–2082.
67. 67 Basu, A., Saito, K., Meyer, K., et al. Stellate cell apoptosis by a soluble mediator from immortalized human hepatocytes. Apoptosis 11:8 (2006), 1391–1400.
68. 68 Khetani, S.R., Bhatia, S.N., Microscale culture of human liver cells for drug development. Nat Biotechnol 26:1 (2008), 120–126.
69. 69 Messner, S., Agarkova, I., Moritz, W., et al. Multi-cell type human liver microtissues for hepatotoxicity testing. Arch Toxicol 87:1 (2013), 209–213.
70. 70 Schutte, J., Hagmeyer, B., Holzner, F., et al. Artificial micro organs–a microfluidic device for dielectrophoretic assembly of liver sinusoids. Biomed Microdevices 13:3 (2011), 493–501.
71. 71 Prodanov, L., Jindal, R., Bale, S.S., et al. Long-term maintenance of a microfluidic 3D human liver sinusoid. Biotechnol Bioeng 113:1 (2016), 241–246.